Meloxicam Stella Dosage/Direction for Use

Administration: Meloxicam STELLA Tablets 7.5mg is administered orally. The tablet should be swallowed whole and must not be halved.
Dosage: Meloxicam STELLA Tablets 7.5mg should be used at the lowest effective dose for the shortest possible time.
Exacerbations of osteoarthrosis: 7.5 mg/day (one 7.5 mg tablet); if necessary, in the absence of improvement, the dose may be increased to 15 mg/day (two 7.5 mg tablets).
Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day (two 7.5 mg tablets).
According to the therapeutic response, the dose may be reduced to 7.5 mg/day (one 7.5 mg tablet).
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms. The patient's need for symptomatic relief and response to therapy should be reevaluated periodically, especially in patients with osteoarthritis.
DO NOT EXCEED THE DOSE OF 15 MG/DAY.
Special Populations: Elderly patients and patients with increased risks for adverse reaction: The recommended dose for long-term treatment of rheumatoid arthritis and ankylosing spondylitis in elderly patients is 7.5 mg per day. Patients with increased risks for adverse reactions should start treatment with 7.5 mg per day.
Renal impairment: In dialysis patients with severe renal failure, the dose should not exceed 7.5 mg per day. No dose reduction is required in patients with mild to moderate renal impairment (i.e. patients with a creatinine clearance of greater than 25 ml/min).
Hepatic impairment: No dose reduction is required in patients with mild to moderate hepatic impairment.
Children and adolescents: Meloxicam STELLA Tablets 7.5mg is contraindicated in children and adolescents aged under 16 years.